SJP 0118

Drug Profile

SJP 0118

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Senju Pharmaceutical
  • Developer Senju Pharmaceutical; Tottori University Hospital
  • Class Antibacterials; Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Blepharitis; Infectious conjunctivitis; Ocular inflammation

Most Recent Events

  • 15 May 2017 Senju Pharmaceutical initiates enrolment in a phase III trial for Infectious conjunctivitis (In adolescents, In children, In adults) in Japan (Instillation) (UMIN000027039)
  • 02 May 2017 Senju Pharmaceutical plans a phase III trial for Infectious conjunctivitis (In adolescents; In children; In adults) in Japan (UMIN000027039)
  • 13 Apr 2017 Senju Pharmaceutical initiates enrolment in a phase III trial for Infectious conjunctivitis in Japan (UMIN000026494)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top